Glucophage XR Settlement: Purepac, Ivax Split Generic Profits For 180 Days
Executive Summary
Ivax and Purepac's exclusivity rights settlement for a generic version of Glucophage XR means FDA has avoided a legal challenge to its interpretation of first-to-file requirements for new ANDAs compared to amended applications